CD40L Antagonism in Rheumatoid Arthritis (RA)
| 対象疾患 | Rheumatoid Arthritis |
|---|---|
| 相 | 第2相 |
| スポンサー | National Institute of Allergy and Infectious Diseases (NIAID) |
| ステータス | 早期終了 |
| 参加者数 | 2 名 |
| 介入（薬剤） | Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi |
| 開始日 | 2023年7月25日 |
| 完了日 | 2025年7月28日 |
| 結果公開日 | 2026年7月20日 |
概要
The primary objective is to determine if the addition of a 12-week course of treatment with VIB4920 to TNFi treatment will result in improved clinical disease control in patients with RA who have had an inadequate response to a TNFi.
Proportion of Participants Achieving Low Disease Activity by Simplified Disease Activity Index (SDAI)
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Dietary Salt in Rheumatoid Arthritis — Vanderbilt University Medical Center
- Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) — University of North Carolina, Chapel Hill
- Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
- A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replace — Smith & Nephew, Inc.